Internship

Regulatory CMC-Cell Therapy Internship

Confirmed live in the last 24 hours

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Summit, NJ, USA

Intern will be based in Summit, NJ.

Category
Risk & Compliance
Biology Lab & Research
Legal & Compliance
Biology & Biotech
Required Skills
PowerPoint/Keynote/Slides
Requirements
  • Graduate student in a Life Sciences Program such as Chemical and Biochemical Engineering, Biomedical Engineering, Molecular Biology, Biochemistry
  • Knowledge of protein synthesis, purification, characterization (SDS-PAGE, Western Blots, Elisa, etc.)
  • Knowledge of cell culture, cell-based assays, flow cytometry is strongly desired
  • Attention to detail, excellent organization skills, good verbal and written communication skills are required
  • Ability to work independently on routine assignments with daily check-ins and to work cooperatively with senior staff providing key assistance on complex assignment
  • Computer experience must include familiarity with Word, Excel and PowerPoint
Responsibilities
  • Support Regulatory CMC Cell Therapy group in the preparation of CMC Regulatory Strategy and submissions and interactions with Global Health Authorities
  • Attend and participate in various Reg CMC and matrix team meetings as needed and applicable
  • Manage and prioritize multiple complex projects

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and cardiovascular conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality and safety standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's AI-driven R&D enhances drug discovery and development efficiency.
  • The $3.5bn agreement with Prime Medicine boosts BMS's cell and gene-therapy pipeline.
  • BMS's commitment to ESG initiatives aligns with industry sustainability trends.

What critics are saying

  • Lawsuits against HRSA and HHS could lead to regulatory and financial challenges.
  • The $6.4 billion lawsuit by UMB poses potential financial liabilities for BMS.
  • The collaboration with AI Proteins may not yield viable therapeutic candidates.

What makes Bristol-Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?